Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
CHRS 
Coherus BioSciences Inc (CHRS)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/01/2025: CHRS (2-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Number of Analysts
7 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $5.67
1 Year Target Price $5.67
| 3 | Strong Buy |
| 1 | Buy |
| 3 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -11.43% | Avg. Invested days 36 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 12/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 164.38M USD | Price to earnings Ratio 2.47 | 1Y Target Price 5.67 |
Price to earnings Ratio 2.47 | 1Y Target Price 5.67 | ||
Volume (30-day avg) 7 | Beta 0.94 | 52 Weeks Range 0.71 - 2.43 | Updated Date 12/1/2025 |
52 Weeks Range 0.71 - 2.43 | Updated Date 12/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.55 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-11-06 | When - | Estimate -0.32 | Actual -0.33 |
Profitability
Profit Margin 55.8% | Operating Margin (TTM) -364.99% |
Management Effectiveness
Return on Assets (TTM) -10.26% | Return on Equity (TTM) 33.11% |
Valuation
Trailing PE 2.47 | Forward PE 41.15 | Enterprise Value 13415577 | Price to Sales(TTM) 0.59 |
Enterprise Value 13415577 | Price to Sales(TTM) 0.59 | ||
Enterprise Value to Revenue 0.05 | Enterprise Value to EBITDA 0.15 | Shares Outstanding 120871013 | Shares Floating 112990223 |
Shares Outstanding 120871013 | Shares Floating 112990223 | ||
Percent Insiders 12.44 | Percent Institutions 43.44 |
Upturn AI SWOT
Coherus BioSciences Inc
Company Overview
History and Background
Coherus BioSciences Inc. was founded in 2010. It focuses on developing and commercializing biosimilar products, initially targeting oncology, immunology and ophthalmology. The company has evolved to also include innovative immuno-oncology therapies.
Core Business Areas
- Biosimilars: Develops and commercializes biosimilars of branded biologic drugs, offering more affordable alternatives to patients. Key focus areas are oncology and immunology.
- Innovative Immunotherapies: Focuses on the development of novel immunotherapies, particularly in the immuno-oncology space. Aim to address unmet medical needs with innovative treatments.
Leadership and Structure
Denny Lanfear serves as the CEO. The company has a typical corporate structure with departments such as Research and Development, Commercial, and Finance.
Top Products and Market Share
Key Offerings
- Udenyca (pegfilgrastim-cbqv): A biosimilar to Neulasta (pegfilgrastim), used to reduce the chance of infection after chemotherapy. Competitors include Amgen (Neulasta), Mylan/Biocon (Fulphila), Sandoz (Ziextenzo). Market share fluctuates but has typically been around 20-25% of the pegfilgrastim market. Revenue from Udenyca in 2023 was approximately $264 million.
- Loqtorzi (toripalimab-tpzi): A next generation PD-1 inhibitor for the treatment of recurrent or metastatic nasopharyngeal carcinoma (NPC). Competitors include Keytruda (pembrolizumab) and Opdivo (nivolumab). It is early stage, so there is no significant market share yet. FDA approved October 2023.
Market Dynamics
Industry Overview
The biosimilars market is growing as patents on originator biologics expire, creating opportunities for companies like Coherus. Immuno-oncology is a rapidly evolving field with significant unmet needs and high growth potential.
Positioning
Coherus BioSciences Inc. is positioned as a player in the biosimilar and immuno-oncology space. Their focus on affordability through biosimilars and innovation through new therapies aims to capture market share.
Total Addressable Market (TAM)
The TAM for biosimilars and immuno-oncology is substantial, estimated in the tens of billions of dollars. Coherus aims to capture a meaningful share of these markets through its biosimilar offerings and innovative pipeline.
Upturn SWOT Analysis
Strengths
- Established biosimilar platform
- Experienced management team
- Approved products generating revenue
- Expanding pipeline of biosimilars and innovative therapies
Weaknesses
- Reliance on biosimilar competition and pricing pressures
- Relatively small compared to larger pharmaceutical companies
- Dependence on regulatory approvals for pipeline products
- High R&D expenses
Opportunities
- Further expansion of biosimilar portfolio
- Successful development and commercialization of innovative therapies
- Strategic partnerships and collaborations
- Expansion into new geographic markets
Threats
- Increased competition in the biosimilar market
- Pricing pressures from payers and regulators
- Clinical trial failures
- Intellectual property challenges
Competitors and Market Share
Key Competitors
- AMGN
- PFE
- BMY
Competitive Landscape
Coherus BioSciences Inc. faces competition from larger, more established pharmaceutical companies. Their strength lies in their focus on biosimilars and innovation in immuno-oncology, but they must navigate pricing pressures and regulatory hurdles.
Major Acquisitions
Surface Oncology
- Year: 2023
- Acquisition Price (USD millions): 65
- Strategic Rationale: Expand immuno-oncology pipeline, acquire clinical-stage assets.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been driven primarily by the adoption of Udenyca.
Future Projections: Future growth depends on the success of their pipeline products and continued sales of Udenyca. Analyst estimates can be found on financial websites.
Recent Initiatives: Recent initiatives include the launch of Loqtorzi and continued development of their pipeline.
Summary
Coherus BioSciences is a mid-sized biopharmaceutical company focused on biosimilars and immuno-oncology. While Udenyca sales are steady, future growth depends on successful pipeline development, specifically Loqtorzi. Increased competition and pricing pressure in the biosimilar market represent ongoing challenges. Acquisition of Surface Oncology aims to boost their innovative pipeline. The company needs to focus on driving product innovation and maintaining a strong competitive positioning.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company SEC filings (10-K, 10-Q), press releases, investor presentations, financial websites (e.g., Yahoo Finance, Google Finance), industry reports.
Disclaimers:
The information provided is for informational purposes only and should not be considered investment advice. Investment decisions should be based on individual due diligence and consultation with a qualified financial advisor. Market share data are estimates and may vary based on source and methodology.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Coherus BioSciences Inc
Exchange NASDAQ | Headquaters Redwood City, CA, United States | ||
IPO Launch date 2014-11-06 | Chairman, President & CEO Mr. Dennis M. Lanfear | ||
Sector Healthcare | Industry Biotechnology | Full time employees 158 | Website https://www.coherus.com |
Full time employees 158 | Website https://www.coherus.com | ||
Coherus Oncology, Inc., a biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel next-generation programmed death receptor-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype (IgG1) monoclonal antibody targeting interleukin 27. It also develops CHS-114, an investigational highly specific human afucosylated IgG1 monoclonal antibody, a chemokine receptor highly expressed on Treg cells in the tumor microenvironment (TME); and CHS-1000, Anti-ILT4 monoclonal antibody for solid tumors. In addition, the company offers GSK4381562, an antibody targeting CD112R to treat tumor cells; YUSIMRY, a biosimilar to Humira for inflammatory diseases characterized by increased production of tumor necrosis factor (TNF) in the body, such as rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, psoriasis, and ulcerative colitis; and CIMERLI, a Lucentis biosimilar to treat neovascular age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema, diabetic retinopathy, and myopic choroidal neovascularization. It has a collaboration agreement with Junshi Biosciences for the co-development and commercialization of toripalimab; agreement with Surface and Adimab LLC; license agreements with Bioeq AG and Genentech, Inc. and Surface and Vaccinex, Inc.; and out-licensing agreement with Novartis Institutes for Biomedical Research, Inc. and GlaxoSmithKline Intellectual Property No. 4 Limited. The company was formerly known as Coherus BioSciences, Inc. and changed its name to Coherus Oncology, Inc. in May 2025. The company was incorporated in 2010 and is based in Redwood City, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.